Structure-based discovery of potent CARM1 inhibitors for colorectal cancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Coactivator-associated arginine methyltransferase 1 (CARM1) is implicated in cell proliferation and gene expression.
• CARM1 is frequently overexpressed in various tumor types, suggesting its role in cancer development.
• Targeting CARM1 offers a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

• To design and evaluate selective inhibitors of CARM1.
• To identify a lead compound with potent CARM1 inhibitory activity.
• To assess the anti-cancer potential of the identified inhibitor in preclinical models.

Main Methods:

• Structure-guided drug design based on previous CARM1 inhibitor scaffolds.
• In vitro enzymatic assays to determine CARM1 inhibition potency (IC50).
• In vitro metabolic stability, molecular modeling, cellular apoptosis assays, and in vivo anti-tumor studies.

Main Results:

• Compound 11f was identified as a potent CARM1 inhibitor with an IC50 of 9 nM.
• Compound 11f demonstrated effective inhibition of CARM1's methylation activity.
• Preclinical studies showed that compound 11f induced cancer cell apoptosis and exhibited significant anti-proliferative effects on colorectal cancer cell lines.
• In vivo studies confirmed the anti-tumor efficacy of compound 11f.

Conclusions:

• Compound 11f is a promising lead candidate for the development of selective CARM1 inhibitors.
• The findings support the therapeutic potential of targeting CARM1 for cancer treatment, particularly for CARM1-related malignancies.
• This study provides a foundation for further development of effective CARM1-targeted therapies.